Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GenSight Biologics S.A. (SIGHT.PA)
EUR0.08
0.00 (-1.11%)
FR PAR Healthcare Biotechnology
Address
74, rue du Faubourg Saint-Antoine 75012
Paris, FR
Paris, FR
CEO
Laurence Rodriguez
Website
gensight-biologics.com
IPO
2016-07-13
ISIN FR0013183985
Also trades on
Euronext Paris · SIGHT.PA (EUR)
Other OTC · GSGTF (USD)
Description
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR0.08
0.00 (-1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
585.2K
Beta
0.64
Float Shares
149.93M
Free Float %
92.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.34% | +0.34% | +8.72% | +0.00% | -20.27% | -15.23% | -59.22% | -89.29% | -98.93% | -98.91% | -98.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.08
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-11.54
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q4'25: -103.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+45.9% ★ Q4'25: +90.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-206,800.0% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,170,500.0% Q4'25: +10,412.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +135.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+54.9% Q4'25: +274.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.14× Q4'25: -0.71× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.00M
est: 3.00M (+0.0%)
|
3.70M
est: 3.03M (+22.0%)
|
4.35M
est: 3.60M (+20.7%)
|
700.0K
est: 3.55M (-80.3%)
|
4.39M
est: 9.79M (-55.1%)
|
5.28M
est: 10.73M (-50.8%)
|
2.58M
est: 4.74M (-45.5%)
|
1.27M
est: 1.98M (-35.9%)
|
2.63M
est: 2.63M (+0.0%)
|
1.0K
est: 2.90M (-100.0%)
|
5.50M
5.50M – 5.50M
+89.7% YoY
|
41.60M
41.60M – 41.60M
+656.4% YoY
|
76.00M
76.00M – 76.00M
+82.7% YoY
|
| EBITDA |
-24.81M
est: -3.00M (-727.0%)
|
-23.77M
est: -3.03M (-683.5%)
|
-32.73M
est: -3.60M (-809.2%)
|
-29.31M
est: -3.55M (-725.7%)
|
-34.13M
est: -9.79M (-248.7%)
|
-25.52M
est: -10.73M (-137.8%)
|
-26.77M
est: -4.74M (-464.9%)
|
-21.73M
est: -1.98M (-999.7%)
|
-14.76M
est: -2.63M (-462.1%)
|
-11.24M
est: -2.90M (-287.6%)
|
-5.50M
-5.50M – -5.50M
-89.7% YoY
|
-41.60M
-41.60M – -41.60M
-656.4% YoY
|
-76.00M
-76.00M – -76.00M
-82.7% YoY
|
| EBIT |
-22.02M
est: -3.00M (-634.0%)
|
-23.99M
est: -3.03M (-690.9%)
|
-33.05M
est: -3.60M (-817.9%)
|
-30.30M
est: -3.55M (-753.5%)
|
-35.06M
est: -9.79M (-258.2%)
|
-26.45M
est: -10.73M (-146.4%)
|
-27.84M
est: -4.74M (-487.2%)
|
-24.76M
est: -1.98M (-1,153.2%)
|
-15.81M
est: -2.63M (-502.4%)
|
-11.71M
est: -2.90M (-303.6%)
|
-5.50M
-5.50M – -5.50M
-89.7% YoY
|
-41.60M
-41.60M – -41.60M
-656.4% YoY
|
-76.00M
-76.00M – -76.00M
-82.7% YoY
|
| Net Income |
-22.08M
est: -99.59M (+77.8%)
|
-24.11M
est: -111.91M (+78.5%)
|
-33.45M
est: -90.01M (+62.8%)
|
-30.71M
est: -88.57M (+65.3%)
|
-34.02M
est: -43.97M (+22.6%)
|
-28.62M
est: -49.79M (+42.5%)
|
-27.62M
est: -70.22M (+60.7%)
|
-26.22M
est: -44.73M (+41.4%)
|
-14.00M
est: -22.25M (+37.1%)
|
-12.04M
est: -52.65M (+77.1%)
|
-65.34M
-72.13M – -31.68M
-24.1% YoY
|
-41.52M
-59.88M – -23.17M
+36.5% YoY
|
-28.18M
-28.18M – -28.18M
+32.1% YoY
|
| SGA |
1.71M
est: 7.85M (-78.2%)
|
3.09M
est: 7.94M (-61.1%)
|
4.66M
est: 9.42M (-50.5%)
|
2.80M
est: 9.29M (-69.9%)
|
3.21M
est: 25.62M (-87.5%)
|
5.89M
est: 28.09M (-79.0%)
|
8.24M
est: 12.41M (-33.6%)
|
7.27M
est: 1.04B (-99.3%)
|
6.07M
est: 1.39B (-99.6%)
|
2.63M
est: 1.53B (-99.8%)
|
2.90B
2.90B – 2.90B
+89.7% YoY
|
21.97B
21.97B – 21.97B
+656.4% YoY
|
40.13B
40.13B – 40.13B
+82.7% YoY
|
| EPS |
-1.36
est: -1.04 (-30.8%)
|
-1.10
est: -1.17 (+5.9%)
|
-1.37
est: -0.94 (-45.7%)
|
-1.08
est: -0.93 (-16.8%)
|
-0.97
est: -0.46 (-111.3%)
|
-0.63
est: -0.52 (-21.2%)
|
-0.60
est: -0.73 (+18.2%)
|
-0.54
est: -0.30 (-79.0%)
|
-0.15
est: -0.15 (+0.0%)
|
-0.08
est: -0.36 (+77.1%)
|
-0.35
-0.49 – -0.21
+1.4% YoY
|
-0.28
-0.40 – -0.16
+20.0% YoY
|
-0.19
-0.19 – -0.19
+32.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.99M
OE per share TTM
-0.19
Owner's Yield
-113.44%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
92.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-7.3K
Shares Outstanding
163.00M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Laurence Rodriguez | Chief Executive Officer & Director | 420.0K | female |
| Botond Roska | Scientific Founder & Chairman of Scientific Advisory Board | — | — |
| Fang Li | Chief Regulatory Affairs & Quality Officer | — | — |
| Jan Eryk Umiastowski | Chief Financial Officer | — | male |
| Jose-Alain Sahel | Scientific Founder, Vice Chairman of Scientific Advisory Board & Director | — | — |
| Julio Benedicto | Senior Vice President of Strategy & Operations | — | male |
| Magali Taiël | Chief Medical Officer | — | — |
| Marion Ghibaudo | Chief Technical Officer of Medical Device | — | female |
| Sabrina Chekroun | Senior Vice President of Regulatory Affairs & Quality | — | female |
| Scott Jeffers | Chief Technical Officer | — | male |
| Barrett Katz | Consultant | — | — |
| Serge Picaud | Scientific Founder & Member of Scientific Advisory Board | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIGHT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
